Document is current
Any future updates will be listed below
-
Authors
Kjaer, Magnus Ruud https://orcid.org/0009-0007-2963-0945
Hanif, Umaer https://orcid.org/0000-0001-8288-5532
Brink-Kjaer, Andreas https://orcid.org/0000-0002-2872-0929
Olsen, Mads
Sum-Ping, Oliver
Carrillo, Oscar
Sands, Scott A.
Redline, Susan https://orcid.org/0000-0002-6585-1610
Stone, Katie L.
Jennum, Poul
Mignot, Emmanuel https://orcid.org/0000-0002-6928-5310
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 16 January 2026
First Online: 9 February 2026
Competing interests
: S.S. received grant support from Apnimed, Prosomnus, and Dynaflex and has served as a consultant for Apnimed, Nox Medical, Inspire Medical Systems, Eli Lilly, Respicardia, LinguaFlex, Forepont, and Achaemenid. He receives royalties for intellectual property pertaining to combination pharmacotherapy for sleep apnea via his Institution. He is a co-inventor of intellectual property pertaining to wearable sleep apnea phenotyping, also via his Institution. His industry interactions are actively managed by his Institution. S.R. received consulting fees from Eli Lilly (not related to the project) and funding from NIH. E.M. received a grant from the ResMed Foundation to study questionnaire predictors of SDB, unrelated to this work. U.H. is an employee of BioSerenity. The remaining authors declare no competing interests.
